A new ray of hope in hepatocellular carcinoma space after Stivarga

 In Drug Development, FDA, Pharmaceutical companies

  • [apss-share counter='1' total_counter='1' http_count='1']

Patients suffering from hepatocellular carcinoma have new ray of hope with Stivarga, recently approved FDA drug for 2nd line treatment after Sorafenib.

There is a growing competition in the Liver cancer space with big pharmaceuticals giants like Eli Lilly, Novartis, Bristol mayer Squibb etc. heading fast. However Stivarga’s approval for HCC promises a prospective future for Bayer with its Sorafenib being already a standard of care for HCC patients.

iPlexusTM – The Intelligence Machine for Life Sciences. Try it now.

By Dr. Esha Pandita
Research Analyst, Science and Research @ Innoplexus

Share this Image On Your Site

Recent Posts

Leave a Comment

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search